Literature DB >> 6614006

Ganglioside GM2 N-acetyl-beta-D-galactosaminidase activity in cultured fibroblasts of late-infantile and adult GM2 gangliosidosis patients and of healthy probands with low hexosaminidase level.

E Conzelmann, H J Kytzia, R Navon, K Sandhoff.   

Abstract

A sensitive assay was developed to assess the ability of extracts from cultured fibroblasts to catabolize ganglioside GM2, in the presence of the natural activator protein but without detergents. This method, which permitted the reliable determination of residual activities as low as 0.1% of normal controls, was then used to measure ganglioside GM2 hydrolase activities in fibroblasts from several hexosaminidase variants. The residual activities thus determined correlated well with the clinical status of the respective proband: infantile Tay-Sachs (0.1% of normal controls), late-infantile (0.5%), and adult GM2 gangliosidoses (2%-4%) and healthy probands with "low hexosaminidase" (11% and 20%). In contrast, beta-hexosaminidase A levels as measured with the synthetic substrate 4-MU-GlcNAc could not be relied on for diagnostic purposes (the late-infantile patient studied retained 80% of the activity of controls).

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6614006      PMCID: PMC1685812     

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  30 in total

1.  Quantitative estimation of sialic acids. II. A colorimetric resorcinol-hydrochloric acid method.

Authors:  L SVENNERHOLM
Journal:  Biochim Biophys Acta       Date:  1957-06

2.  Specificity of human liver hexosaminidases A and B against glycosphingolipids GM2 and GA2. Purification of the enzymes by affinity chromatography employing specific elution.

Authors:  K Sandhoff; E Conzelmann; H Nehrkorn
Journal:  Hoppe Seylers Z Physiol Chem       Date:  1977-07

3.  Low levels of beta hexosaminidase A in healthy individuals with apparent deficiency of this enzyme.

Authors:  R Navon; B Geiger; Y B Yoseph; M C Rattazzi
Journal:  Am J Hum Genet       Date:  1976-07       Impact factor: 11.025

4.  Ganglioside catabolism in hexosaminidase A-deficient adults.

Authors:  J F Tallman; R O Brady; R Navon; B Padeh
Journal:  Nature       Date:  1974-11-15       Impact factor: 49.962

5.  Hexosaminidase-A and hexosaminidase-B: studies in Tay-Sachs' and Sandhoff's disease.

Authors:  S K Srivastava; E Beutler
Journal:  Nature       Date:  1973-02-16       Impact factor: 49.962

6.  Apparent deficiency of hexosaminidase A in healthy members of a family with Tay-Sachs disease.

Authors:  R Navon; B Padeh; A Adam
Journal:  Am J Hum Genet       Date:  1973-05       Impact factor: 11.025

7.  Absence of hexosaminidase A and B in a normal adult.

Authors:  J C Dreyfus; L Poenaru; L Svennerholm
Journal:  N Engl J Med       Date:  1975-01-09       Impact factor: 91.245

8.  Adult GM2 gangliosidosis in association with Tay-Sachs disease: a new phenotype.

Authors:  R Navon; Z Argov; N Brand; U Sandbank
Journal:  Neurology       Date:  1981-11       Impact factor: 9.910

9.  Complexing of glycolipids and their transfer between membranes by the activator protein for degradation of lysosomal ganglioside GM2.

Authors:  E Conzelmann; J Burg; G Stephan; K Sandhoff
Journal:  Eur J Biochem       Date:  1982-04-01

10.  Specific radioactive labeling of terminal n-acetylgalactosamine of glycosphingolipids by the galactose oxidase-sodium borohydride method.

Authors:  Y Suzuki; K Suzuki
Journal:  J Lipid Res       Date:  1972-09       Impact factor: 5.922

View more
  21 in total

1.  Quantitative correlation between the residual activity of beta-hexosaminidase A and arylsulfatase A and the severity of the resulting lysosomal storage disease.

Authors:  P Leinekugel; S Michel; E Conzelmann; K Sandhoff
Journal:  Hum Genet       Date:  1992-03       Impact factor: 4.132

Review 2.  Clinical neurogenetics: neuropathic lysosomal storage disorders.

Authors:  Gregory M Pastores; Gustavo H B Maegawa
Journal:  Neurol Clin       Date:  2013-11       Impact factor: 3.806

3.  Hexosaminidase assays.

Authors:  Michaela Wendeler; Konrad Sandhoff
Journal:  Glycoconj J       Date:  2009-11       Impact factor: 2.916

Review 4.  Identification and characterization of pharmacological chaperones to correct enzyme deficiencies in lysosomal storage disorders.

Authors:  Kenneth J Valenzano; Richie Khanna; Allan C Powe; Robert Boyd; Gary Lee; John J Flanagan; Elfrida R Benjamin
Journal:  Assay Drug Dev Technol       Date:  2011-06       Impact factor: 1.738

5.  Hereditary heat-labile hexosaminidase B: a variant whose homozygotes synthesize a functional HEX A.

Authors:  R Navon; R Kopel; J Nutman; A Frisch; E Conzelmann; K Sandhoff; A Adam
Journal:  Am J Hum Genet       Date:  1985-01       Impact factor: 11.025

6.  Frequency of hexosaminidase A variant alleles among Ashkenazi Jews and prenatal diagnosis of GM2 gangliosidosis.

Authors:  R Navon; A Adam
Journal:  Am J Hum Genet       Date:  1985-09       Impact factor: 11.025

7.  Hexosaminidase A activity in skin fibroblasts from various types of GM2 gangliosidosis using a fluorogenic sulphated substrate.

Authors:  K Inui; T Yutaka; S Okada; H Yabuuchi; D A Wenger; R J Desnick
Journal:  J Inherit Metab Dis       Date:  1985       Impact factor: 4.982

8.  Splice junction mutation in some Ashkenazi Jews with Tay-Sachs disease: evidence against a single defect within this ethnic group.

Authors:  R Myerowitz
Journal:  Proc Natl Acad Sci U S A       Date:  1988-06       Impact factor: 11.205

9.  Diagnosis of infantile and juvenile forms of GM2 gangliosidosis variant 0. Residual activities toward natural and different synthetic substrates.

Authors:  H J Kytzia; U Hinrichs; K Sandhoff
Journal:  Hum Genet       Date:  1984       Impact factor: 4.132

Review 10.  [Sphingolipid storage diseases of the central nervous system: bases of biochemical and clinical heterogeneity].

Authors:  K Sandhoff; L Quintern
Journal:  Naturwissenschaften       Date:  1988-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.